Chikungunya Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials

Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
Condition:   Chikungunya Intervention:   Other: 15 years Follow-up group Sponsor:   Centre Hospitalier Universitaire de la Réunion Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2021 Category: Research Source Type: clinical trials

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)
Condition:   Chikungunya Virus Infection Intervention:   Biological: VLA1553 Sponsor:   Valneva Austria GmbH Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2021 Category: Research Source Type: clinical trials

Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
Condition:   Chikungunya Intervention:   Other: 15 years Follow-up group Sponsor:   Centre Hospitalier Universitaire de la Réunion Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2021 Category: Research Source Type: clinical trials

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)
Condition:   Chikungunya Virus Infection Intervention:   Biological: VLA1553 Sponsor:   Valneva Austria GmbH Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2021 Category: Research Source Type: clinical trials

Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
Condition:   Chikungunya Intervention:   Other: 15 years Follow-up group Sponsor:   Centre Hospitalier Universitaire de la Réunion Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2021 Category: Research Source Type: clinical trials

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)
Condition:   Chikungunya Virus Infection Intervention:   Biological: VLA1553 Sponsor:   Valneva Austria GmbH Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2021 Category: Research Source Type: clinical trials

Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
Condition:   Chikungunya Intervention:   Other: 15 years Follow-up group Sponsor:   Centre Hospitalier Universitaire de la Réunion Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2021 Category: Research Source Type: clinical trials

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)
Condition:   Chikungunya Virus Infection Intervention:   Biological: VLA1553 Sponsor:   Valneva Austria GmbH Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2021 Category: Research Source Type: clinical trials

Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
Condition:   Chikungunya Intervention:   Other: 15 years Follow-up group Sponsor:   Centre Hospitalier Universitaire de la Réunion Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2021 Category: Research Source Type: clinical trials

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)
Condition:   Chikungunya Virus Infection Intervention:   Biological: VLA1553 Sponsor:   Valneva Austria GmbH Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2021 Category: Research Source Type: clinical trials